Orexin receptor
G-protein-coupled receptor From Wikipedia, the free encyclopedia
The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin. There are two variants, OX1 and OX2, each encoded by a different gene (HCRTR1, HCRTR2).[1]
Both orexin receptors exhibit a similar pharmacology – the 2 orexin peptides, orexin-A and orexin-B, bind to both receptors and, in each case, agonist binding results in an increase in intracellular calcium levels. However, orexin-B shows a 5- to 10-fold selectivity for orexin receptor type 2, whilst orexin-A is equipotent at both receptors.[2][3]
Several orexin receptor antagonists are in development for potential use in sleep disorders.[4] The first of these, suvorexant, has been on the market in the United States since 2015.[5] There were two orexin agonists under development as of 2019[update].[6]
Ligands
Summarize
Perspective
Several drugs[7] acting on the orexin system are under development, either orexin agonists for the treatment of conditions such as narcolepsy, or orexin antagonists for insomnia. In August 2015, Nagahara et al. published their work in synthesizing the first HCRT/OX2R agonist, compound 26, with good potency and selectivity.[8]
No neuropeptide agonists are yet available, although synthetic orexin-A polypeptide has been made available as a nasal spray and tested on monkeys. One non-peptide antagonist is currently available in the U.S., Merck's suvorexant (Belsomra),[9] two additional agents are in development: SB-649,868 by GlaxoSmithKline, for sleep disorders, and ACT-462206, currently in human clinical trials.[10] Another drug in development, almorexant (ACT-078573) by Actelion, was abandoned due to adverse effects. Lemborexant, an orexin receptor antagonist, was approved for use in the United States in 2019.
Most ligands acting on the orexin system so far are polypeptides modified from the endogenous agonists orexin-A and orexin-B, however there are some subtype-selective non-peptide antagonists available for research purposes.
Agonists
Non-selective
- Orexins – dual OX1 and OX2 receptor agonists
- AEX-5 – selective OX1 receptor agonist; also a cathepsin H inhibitor and dopamine reuptake inhibitor[11]
- AEX-19 – dual OX1 and OX2 receptor agonist[12]
- AEX-24 – selective OX2 receptor agonist; also an "S1R" agonist[13]
Selective
- Alixorexton – selective oral OX2 receptor agonist[14]
- ALKS-2680 — selective oral OX2 receptor agonist[15]
- Danavorexton (TAK-925) – selective OX2 receptor agonist
- E-2086 – selective OX2 receptor agonist[16]
- Firazorexton (TAK-994) – selective OX2 receptor agonist[17][18]
- Oveporexton (TAK-861) – selective OX2 receptor agonist
- SB-668875 – selective OX2 receptor agonist
- Suntinorexton – selective OX2 receptor agonist[17][18][19]
- PhotOrexin – photoswitchable orexin-B analogue to control the OX2 receptor at nanomolar concentration in vivo.[20]
Antagonists
Non-selective
- Almorexant (ACT-078573) – dual OX1 and OX2 receptor antagonist
- Daridorexant (Quviviq; ACT-541468) – dual OX1 and OX2 receptor antagonist
- Filorexant (MK-6096) – dual OX1 and OX2 receptor antagonist
- GSK-649868 (SB-649868) – dual OX1 and OX2 receptor antagonist
- Lemborexant (Dayvigo) – dual OX1 and OX2 receptor antagonist
- Suvorexant (Belsomra) – dual OX1 and OX2 receptor antagonist
- Vornorexant (ORN-0829, TS-142) – dual OX1 and OX2 receptor antagonist
Selective
- ACT-335827 – selective OX1 receptor antagonist
- AZD-4041 – selective OX1 receptor antagonist[21]
- C4X-3256 (INDV-2000) – selective OX1 receptor antagonist[22]
- CVN-766 – selective OX1 receptor antagonist[23]
- EMPA – selective OX2 receptor antagonist
- JNJ-10397049 – selective OX2 receptor antagonist
- Nivasorexant (ACT-539313) – selective OX1 receptor antagonist
- Rocavorexant – selective OX1 receptor antagonist
- RTIOX-276 – selective OX1 receptor antagonist
- SB-334867 – selective OX1 receptor antagonist
- SB-408124 – selective OX1 receptor antagonist
- Seltorexant (MIN-202, JNJ-42847922, JNJ-922) – selective OX2 receptor antagonist
- TCS-OX2-29 – selective OX2 receptor antagonist
- Tebideutorexant (JNJ-61393215; JNJ-3215) – selective OX1 receptor antagonist
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.